Mon. 11 Mar 2024, 8:04am ET
Benzinga
Biotech, News, Health Care, General
- Dose ordered and robust HiSCRs were rapidly demonstrated with about a third of patients achieving HiSCR100, or resolution of abscesses and nodules, by week 16 and through week 32
- Deep and consistent HiSCR responses were observed for placebo patients switching to active treatment
- Marked reductions in draining tunnels and skin pain also contributed to clinically meaningful improvements in quality of life
- Potential for differentiation was demonstrated with both high clinical responses as well as a favorable safety profile consistent with the IL-17A class and previous izokibep experience